Eli Lilly CEO expects new weight loss pill to be approved next year
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.
Eli Lilly CEO says the company sees ‘significant common cause’ with Trump administration
Eli Lilly CEO said he believed the company could find “significant common cause” with the Trump administration, even if there were reasons for concern.
Eli Lilly was hoping weight loss drug demand would be even bigger
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.
SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start your day.
Eli Lilly CEO tells Bloomberg TV company sees weight loss pill approval in 2026
Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an
Eli Lilly’s stock falls as weight-loss drug sales disappoint
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
Hims & Hers in focus as Eli Lilly obesity drug sales disappoint
Eli Lilly (NYSE:LLY) shares sold off on Tuesday after the Indiana-based pharma giant's Q4 and 2024 preliminary sales results for its obesity therapy tirzepatide fell short of Street forecasts. Novo Nordisk (NVO),
Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall
Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.
Zacks.com on MSN7h
Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip
Eli Lilly slashes the revenue guidance for the fourth quarter and fiscal 2024 but offers a bullish outlook for 2025.
Eli Lilly: Big 2025 Ahead, But Execution Risks Exist
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
The David Rubenstein Show: Dave Ricks(Podcast
Peer Conversations explores successful leadership through the personal and professional choices of the most influential ...
FiercePharma1d
JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Lilly asks US government to pause drug price negotiations, Bloomberg News reports
Eli Lilly has asked the U.S. government to pause price negotiations for prescription drugs, Bloomberg News reported on Monday ...
24/7 Wall St7h
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 465.16% and ...
Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.
The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...